United States Patent 6,096,331 Scope and Claim-Chart Analysis for Cremophor-Free Taxane Dosing (≤3-Hour Administration, No Premedication)

US Patent 6,096,331 is a method-and-formulation estate focused on systemic administration of a taxane in a cremophor-free formulation, delivered over short infusion times (<3 hours; narrower embodiments <2 hours and <1 hour), without premedication, and often at high dose ranges (including at least ~135 mg/m2, 175 mg/m2, 250 mg/m2 and higher bands). The independent claim core is a time-compressed, excipient-restricted administration paradigm, with extensive dependent fallbacks tying the same dosing concept to hematologic and neurologic toxicity reduction, tumor site concentration goals, prostate cancer via medical orchiectomy, and unit dosage/handling characteristics (concentration, reconstitution stability, tubing compatibility, low infusion volume).

What does US Patent 6,096,331 claim: cremophor-free taxane administration without premedication?

Which parts of the claim set are “core” vs. “fallback”?

The claims cluster into four functional buckets:

Core administration methods (independent claim 1; independent claim 7).
- Cremophor-free taxane systemic administration
- Dose range: ~30 mg/m2 to ~1000 mg/m2
- Administration time: <3 hours (claim 1)
- No premedication (both core routes)
- Treatment-cycle limits in claim 7 (≤2 weeks)
Toxicity reduction methods (hematologic and cerebral/neurologic).
- Claims 15–18 depend on the same cremophor-free systemic dosing concept
- Optional albumin appears as a formulation enhancer.
Tumor treatment / tumor-site concentration methods and formulations.
- Claims 19–25 and 26–28 cover primary tumors and metastatic tumors by “achieving high local concentration”
- Claims 29–30 cover medical orchiectomy for prostatic cancer
Formulation and unit dosage forms (handling, concentration, stability, tubing compatibility).
- Claims 31–38 define unit dosage form and delivery attributes
- Claims 34–35 anchor reconstitution stability and IV tubing compatibility at concentration >1.3 mg/ml.

What is the independent claim “center of gravity”?

Claim 1 defines an administration method with all of these limitations in combination:

Taxane (the claim uses “taxane” generically)
Systemic administration in a dose range 30–1000 mg/m2
Pharmaceutically acceptable formulation that is substantially free of cremophor
Over an administration time of less than 3 hours
Without the use of premedication

Claim 7 is an independent continuation focusing on cycle duration:

Same cremophor-free systemic dosing concept
Treatment cycle ≤2 weeks
Administration time <2 hours is called out in dependent claim 10, and no premedication remains a required feature in the base of claim 7.

Practical reading for freedom-to-operate: any system that maintains (i) cremophor-free formulation, (ii) systemic dosing, (iii) <3 hours infusion time, and (iv) no premedication falls into the tightest infringement-risk zone, regardless of whether the user chooses to target toxicity reduction or specific cancer labels.

How do the claims narrow infringement risk: time, dose, and “no premedication”

Administration time bands: <3 hours is the headline, but <2 and <1 are meaningful

Claim 1: administration time <3 hours
Claim 5: narrower: <2 hours
Claim 52: narrower: <1 hour
Parallel time limits in the claim 7 family:
- Claim 10: administration period <2 hours
- Claim 53: administration period <1 hour
Unit dosage “trigger” time:
- Claim 31: unit dosage form sized for administration at dose 30–1000 mg/m2 over <3 hours

Dose bands: does “high-dose” matter legally?

Yes. The specification of dose thresholds is used repeatedly to create narrower claim embodiments:

Base dose band (broad): 30–1000 mg/m2 (claims 1 and 7)
Narrower thresholds:
- ≥135 mg/m2 (claims 2 and 8)
- ≥175 mg/m2 (claims 6 and 9)
- ≥250 mg/m2 (claims 14, 37, and 54–55)
- Additional explicit banding:
  - >80 mg/m2 to 700 mg/m2 (claims 40 and 42)
Unit sizing equivalents:
- Claim 41: unit dosage form sized for >80 up to 700 mg/m2 over <3 hours

Risk implication: Even if a generic or alternative formulation targets cremophor-free and short infusion, staying below the specific cutoffs can shift the infringement analysis from broader claim 1/7 coverage to narrower dependent-claim coverage.

“Without the use of premedication”: the strongest exclusion lever

Across both core independent claims, premedication is expressly excluded. Dependent claim 56–57 expand the “no helpers” concept in a formulation-negative manner:

Claim 56–57: formulation is free of agents which aid recovery from hematologic toxicity of taxane
(This is not framed as “premedication” directly, but it functionally narrows what can be combined with the cremophor-free formulation.)

What does “substantially free of cremophor” practically cover in this patent?

Cremophor-free appears as both an administration limitation and a formulation limitation

Multiple claims repeat “substantially free of cremophor” (or “free of cremophor”) so the patent supports both:

Method infringement theories: the patient receives the cremophor-free formulation
Formulation infringement theories: the formulation itself meets the cremophor restriction

Key claim points:

Core: Claim 1 and 7 use “substantially free of cremophor”
Specific dependents use “free of cremophor”:
- Claim 43 (claim 1 free of cremophor)
- Claim 44 (claim 7 free of cremophor)
- Claim 48 (formulation of claim 22 free of cremophor)
- Claim 51 (unit non-aqueous formulation free of cremophor)
- Others (claims 45–47, 49–50)

Practical reading: the patent is built to capture both “substantially free” formulations and “free” formulations, so a defendant cannot rely on minor residual cremo/related surfactant arguments without confronting dependent claim fallbacks.

What formulations are protected: albumin, non-aqueous, bolus vs infusion, concentration >1.3 mg/ml

Albumin is an explicit formulation enhancer

Albumin appears in multiple dependent claims:

Claim 16: hematologic toxicity reduction method, with formulation further comprising albumin
Claim 18: neurologic toxicity reduction method, with albumin
Claim 21, 28: primary tumor / metastatic tumor methods with albumin
Claim 30: medical orchiectomy method with albumin
Claim 24: tumor-site concentration formulation with albumin

Legal function: albumin provides additional claim hooks that can catch formulations that otherwise meet the cremophor-free/time/dose limits.

Bolus vs infusion: a distinct handling pathway

Claim 3 and Claim 11: formulation administered as a bolus injection
Claim 3/11 dependents add dose thresholds (≥135 mg/m2, ≥175 mg/m2)

This matters because some competitors may attempt to argue that “administration time” relates only to infusion, not bolus. The patent expressly includes “bolus” pathways.

Non-aqueous and dry powder are included

Unit dosage claim set includes alternative dosage forms:

Claim 32: unit dosage form where taxane is administered as non-aqueous formulation, substantially free of cremophor
Claim 33: unit dosage form as a dry powder formulation

Concentration, tubing compatibility, and reconstitution stability: operational targets

Claims that are likely to map to specific manufacturing and packaging claims:

Claim 34: lyophilized taxane formulation:
- reconstitutable at concentrations >1.3 mg/ml
- stable for at least 3 days
Claim 35: taxane formulation suitable for standard IV infusion tubing:
- concentration >1.3 mg/ml
Claim 36: formulation suitable for dose delivery over <3 hrs
Claim 37: formulation dose comprises ~250–300 mg/m2
Claim 38: volume constraint: delivered in volume <200 ml

Risk implication: even if a competitor avoids cremophor and uses short infusion, it may still need to match these operational features to avoid dependent-claim coverage.

How broad is the “taxane” coverage: does the claim identify docetaxel/paclitaxel?

The text provided does not specify a particular taxane (e.g., paclitaxel, docetaxel). The claims use “a taxane” generically. The scope therefore reads as covering taxane actives broadly unless the claim construction is limited by the specification, which is not provided here.

Business consequence: the estate is positioned to cover multiple taxane lines if they are delivered in a cremophor-free, premedication-free, short-time systemic regimen.

What tumor indications and mechanisms are covered: primary tumors, metastases, orchiectomy

Primary tumors with “high local concentration”

Claim 19: treatment of primary tumors by achieving high local concentration of taxane at tumor site
Claim 20: primary tumors include:
- prostate, testes, lung, kidney, pancreas, bone, spleen, liver, brain
Claim 22–25: corresponding formulation claims for primary tumors with:
- cremophor-free
- dose 30–1000 mg/m2
- possible albumin
- formulation shows reduced cerebral/neurologic toxicity

Metastatic tumors with “high local concentration”

Claim 26: treatment of metastatic tumors by achieving high local concentration at site of metastases
Claim 27: metastasis sites:
- lung, bone, liver, brain
Claim 28: formulation includes albumin option

Prostate cancer via medical orchiectomy

Claim 29: prostatic cancer treatment by inducing medical orchiectomy
- administered dose 30–1000 mg/m2 in cremophor-free formulation
Claim 39: formulation useful for reduction of serum testosterone levels

Risk implication: the claims are not limited to oncology response endpoints in the text provided; they are framed around administration goals (local concentration; orchiectomy/serum testosterone reduction). That can broaden the commercial design space a manufacturer must consider.

How the toxicity-reduction claims expand the patent’s infringement surface

Hematologic toxicity reduction

Claim 15: method for reducing hematologic toxicity
- systematic dosing in cremophor-free formulation
Claim 16: adds albumin in formulation

Cerebral/neurologic toxicity reduction

Claim 17: method for reducing cerebral or neurologic toxicity
Claim 18: adds albumin

“No agents which aid recovery from hematologic toxicity”

Claim 56–57: formulation free of agents which aid recovery from hematologic toxicity

Legal function: these dependents can capture competitors who add supportive agents (as opposed to corticosteroid premedication). The patent language shifts from “no premedication” to “no hematologic recovery aids,” creating a second axis of restriction.

Which dose/volume/concentration limitations are most likely to appear in infringement disputes?

The strongest technical hooks, as phrased in dependent claims, are:

Time compression: <3 hours, with <2 and <1 as narrow rails
High dose: thresholds at ≥135, ≥175, ≥250 mg/m2, plus >80 to 700 mg/m2 banding
Cremophor status: “substantially free” in independents, “free of cremophor” in multiple dependents
Premedication absence: explicit in core method claims
Handling constraints:
- concentration >1.3 mg/ml
- reconstitution stability ≥3 days
- standard IV tubing compatibility
- infusion volume <200 ml
Dosage form types: non-aqueous, dry powder, lyophilized, and bolus injection routes

These are the parameters a litigation or Paragraph IV-style analysis tends to map to formulation dossiers, clinical protocols, and manufacturing specs.

US Patent 6,096,331 claim mapping summary (by limitation category)

A. Core administration limitations

Claim(s)	Key limitations	Scope effect
1	taxane; systemic; 30–1000 mg/m2; cremophor-free; <3 hours; no premedication	Broad core method risk
7	same core; cremophor-free; no premedication; cycle ≤2 weeks	Adds schedule restriction

B. Tightening limitations (time)

Claim(s)	Limitation	Scope effect
5, 10	<2 hours	narrower but important
52, 53	<1 hour	narrowest time rail

C. Tightening limitations (dose)

Claim(s)	Limitation	Scope effect
2, 8	≥135 mg/m2	narrower dose rail
6, 9	≥175 mg/m2	narrower dose rail
14, 54, 55	≥250 mg/m2	narrowest dose rail
40, 41, 42	>80 to 700 mg/m2	intermediate dosing rail

D. Administration route and unit form

Claim(s)	Limitation
3, 11	bolus injection
31, 32	unit dosage vessel; non-aqueous substantially cremophor-free
33	dry powder
38	volume <200 ml

E. Formulation concentration/stability/tubing

Claim(s)	Limitation
34	lyophilized; reconstitute >1.3 mg/ml; stable ≥3 days
35	standard IV tubing compatibility; concentration >1.3 mg/ml

F. Clinical purpose expansions

Claim(s)	Indication/mechanism	Added feature
15–18	reduce hematologic and neurologic toxicity	albumin option
19–25	primary tumors; local concentration; listed tumor types	albumin + neuro-toxicity reduction formulation
26–28	metastatic tumors; local concentration; listed sites	albumin option
29–30	prostatic cancer; medical orchiectomy	albumin option
39	reduction of serum testosterone levels	formulation utility

Patent landscape: what this claim set implies about competitive design-arounds in the US

Without the prosecution history, specification details, and the Orange Book record, the patent landscape analysis can still be done at the claim-logic level:

Design-arounds most relevant to this claim set

Reintroduce cremophor (or cremophor-like surfactant) into the formulation
- Would aim to avoid “substantially free/free of cremophor” limitations.
Use premedication in the regimen
- Directly avoids the “without premedication” limitations in claims 1 and 7.
Extend administration time above the claimed thresholds
- Moving to ≥3 hours avoids claim 1; ≥2 hours avoids claim 5/10; ≥1 hour avoids claim 52/53.
Avoid the stated dose thresholds when targeting dependent claims
- Staying below 135 mg/m2, 175 mg/m2, or 250 mg/m2 can reduce dependent-claim exposure.
Remove specific formulation properties
- Avoid concentration >1.3 mg/ml, adjust reconstitution stability profile (<3 days), or ensure incompatibility with “standard IV infusion tubing” claims (though those are harder to manufacture-specific avoid).
Avoid bolus dosing
- Some competitors may choose infusion modalities to reduce “bolus injection” dependents.

Where competitors are most likely to face infringement risk

If a product is cremophor-free, uses short (<3 hour) systemic administration, and uses no premedication, it is structurally aligned with the independent claims.
If it also satisfies high dose rails and operational concentration/stability/tubing properties, it is positioned to meet multiple dependent claim targets.

How strong is the patent estate for licensing or litigation leverage (claim structure only)

Even without knowing the prosecution outcome, the claim structure suggests:

High breadth at the method level (generic “taxane,” wide dose range, “substantially free of cremophor,” and <3 hour administration)
Multiple dependent fallbacks that keep coverage active across variations:
- time (<2, <1)
- dose thresholds (≥135/175/250)
- administration route (bolus)
- toxicity reduction purposes
- tumor-site concentration and orchiectomy mechanism
- formulation handling specs (lyophilized, >1.3 mg/ml, stable ≥3 days, IV tubing compatibility)
Multiple formulation-centric targets (unit dosage forms, non-aqueous/dry powder, albumin inclusion)

For litigation strategy, this increases the chance that a challenger will still find at least one claim path that reads on accused dosing regimens or formulation specs, even if they successfully avoid a single parameter.

Key Takeaways

US 6,096,331 is built around a combined regimen: systemic taxane dosing using a cremophor-free formulation, delivered without premedication, over <3 hours (with additional narrower time rails <2 and <1 hours).
The claims include multiple dependent fallbacks that broaden exposure across high dose thresholds (≥135/175/250 mg/m2 and >80 to 700 mg/m2 bands), bolus administration, and formulation/handling attributes (notably >1.3 mg/ml, lyophilized reconstitution stability ≥3 days, IV tubing compatibility, and volume <200 ml).
Indication coverage is expansive at the claim level: hematologic and neurologic toxicity reduction, primary tumor and metastatic treatment via tumor-site concentration, and prostate cancer via medical orchiectomy/serum testosterone reduction.
For design-around planning, the most direct claim-evasion levers are: use premedication, use a formulation not substantially free of cremophor, and extend infusion time beyond the claimed limits; avoiding specific dose thresholds and formulation concentration/stability attributes can reduce dependent-claim exposure.

FAQs

If a competitor uses a cremophor-free taxane but includes premedication, does that avoid US 6,096,331?
The core independent claims (1 and 7) require “without the use of premedication,” so premedication is a direct avoidance parameter.
Does US 6,096,331 cover both bolus injection and infusion delivery?
Yes. The claim set includes bolus injection dependents (claims 3 and 11) tied to the core dosing concept.
Is the claimed drug substance restricted to paclitaxel or docetaxel?
The provided claim text uses “taxane” broadly, without naming a specific taxane in the claims shown.
What concentration and stability targets appear in the claim set?
Claims 34–35 target reconstitution at concentrations >1.3 mg/ml, stability ≥3 days for lyophilized formulations, and IV tubing compatibility with concentration >1.3 mg/ml.
Can toxicity-support formulations create exposure even when cremophor is absent?
Yes. The claims include both toxicity-reduction method claims and formulation exclusions for agents that aid recovery from hematologic toxicity (claims 56–57), creating a second axis beyond cremophor.

References

United States Patent No. 6,096,331 (claims provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0961612	⤷ Start Trial	CA 2009 00036	Denmark	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	91613	Luxembourg	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	09C0050	France	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	C00961612/01	Switzerland	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	SZ 41/2009	Austria	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	441	Finland	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	2009C/046	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,096,331